TY - JOUR AB - Sickle cell disease (SCD) is a genetic disorder that predisposes affected individuals to a range of complications, including an increased susceptibility to viral infections. These infections present significant clinical challenges due to the underlying immunocompromised state in SCD patients. This review examines the interaction between viral infections and SCD, highlighting the vulnerabilities and the impact of these infections on morbidity and mortality in this population. Advances in antiviral therapies have significantly improved outcomes, yet managing viral infections in SCD patients requires special consideration due to drug-to-drug interactions, altered pharmacokinetics, and the potential exacerbation of SCD-related complications. Additionally, vaccination strategies against viral infections and the emerging role of prophylactic antiviral treatments are discussed as critical components of infection prevention. By focusing on both established and novel antiviral treatments, this article aims to provide a comprehensive overview of the challenges and opportunities in managing viral infections in patients with SCD. AU - Sahu, T.* AU - Jagzape, A.T.* AU - Sinha, M.* AU - Sinha, R.* AU - Verma, H.K. C1 - 75033 C2 - 57726 TI - New frontiers in sickle cell disease: The role of antiviral therapies and emerging drugs in managing viral infections. JO - World J. Virol. VL - 14 IS - 2 PY - 2025 SN - 2220-3249 ER - TY - JOUR AB - RNA viruses continue to pose significant threats to global public health, necessitating a profound understanding of their pathogenic mechanisms and the development of effective therapeutic interventions. This manuscript provides a comprehensive overview of emerging perspectives on RNA virus-mediated infections, spanning from the intricate intricacies of viral pathogenesis to the forefront of innovative therapeutic strategies. A critical exploration of antiviral drugs sets the stage, highlighting the diverse classes of compounds that target various stages of the viral life cycle, underscoring the ongoing efforts to combat viral infections. Central to this discussion is the exploration of RNA-based therapeutics, with a spotlight on messenger RNA (mRNA)-based approaches that have revolutionized the landscape of antiviral interventions. Furthermore, the manuscript delves into the intricate world of delivery systems, exploring inno-vative technologies designed to enhance the efficiency and safety of mRNA vaccines. By analyzing the challenges and advancements in delivery mechanisms, this review offers a roadmap for future research and development in this critical area. Beyond conventional infectious diseases, the document explores the expanding applications of mRNA vaccines, including their promising roles in cancer immunotherapy and personalized medicine approaches. This manuscript serves as a valuable resource for researchers, clinicians, and policymakers alike, offering a nuanced perspective on RNA virus pathogenesis and the cutting-edge therapeutic interventions. By synthesizing the latest advancements and challenges, this review contributes significantly to the ongoing discourse in the field, driving the development of novel strategies to combat RNA virus-mediated infections effectively. AU - Mohanty, P.* AU - Panda, P.* AU - Acharya, R.K.* AU - Pande, B.* AU - Bhaskar, L.* AU - Verma, H.K. C1 - 69768 C2 - 53865 SP - 242-255 TI - Emerging perspectives on RNA virus-mediated infections: From pathogenesis to therapeutic interventions. JO - World J. Virol. VL - 12 IS - 5 PY - 2023 SN - 2220-3249 ER - TY - JOUR AB - Microbial co-infections are another primary concern in patients with coronavirus disease 2019 (COVID-19), yet it is an untouched area among researchers. Preliminary data and systematic reviews only show the type of pathogens responsible for that, but its pathophysiology is still unknown. Studies show that these microbial co-infections are hospital-acquired/nosocomial infections, and patients admitted to intensive care units with invasive mechanical ventilation are highly susceptible to it. Patients with COVID-19 had elevated inflammatory cytokines and a weakened cell-mediated immune response, with lower CD4+ T and CD8+ T cell counts, indicating vulnerability to various co-infections. Despite this, there are only a few studies that recommend the management of co-infections. AU - Sahu, T.* AU - Verma, H.K. AU - Bhaskar, L.V.K.S.* C1 - 64784 C2 - 52482 SP - 107-110 TI - Bacterial and fungal co-infection is a major barrier in COVID-19 patients: A specific management and therapeutic strategy is required. JO - World J. Virol. VL - 11 IS - 2 PY - 2022 SN - 2220-3249 ER - TY - JOUR AB - Patients with lymphoid malignancies are at a higher risk of coronavirus disease 2019 (COVID-19) infection due to their immunocompromised state and results in higher mortality rates in these patients. Anti-CD 20 therapy is one of the leading causes of immunosuppression that worsens in COVID-19 cases. COVID-19 vaccines, on the other hand, appear to be less beneficial to these patients. App-ropriate treatment and recommendations are required for these COVID-19 patients with lymphoid malignancies. AU - Sahu, T.* AU - Verma, H.K. AU - Lvks, B.* C1 - 66383 C2 - 53161 SP - 204-207 TI - Management of SARS-CoV-2 infection is a major challenge in patients with lymphoid malignancies: Warrants a clear therapeutic strategy. JO - World J. Virol. VL - 11 IS - 4 PY - 2022 SN - 2220-3249 ER -